Table 5.
Effectiveness endpoints in the overall population and patient subgroups.
| Overall | Primary IVL | Secondary IVL | Bailout IVL | ISR IVL | p | |
|---|---|---|---|---|---|---|
| No. of IVL treated lesions | 110 | 25 | 51 | 11 | 23 | |
| IVL device delivery and treatment | 109 (99.1) | 25 (100) | 50 (98) | 11 (100) | 23 (100) | 0.99 |
| DES/DCB successful expansion | 107 (97.3) | 25 (100) | 49 (96.1) | 10 (90.9) | 23 (100) | 0.41 |
| Final TIMI 3 flow | 110 (100) | 25 (100) | 51 (100) | 11 (100) | 23 (100) | – |
| Residual DS < 20% | 93 (84.6) | 23 (92) | 42 (82.4) | 8 (72.7) | 20 (87) | 0.45 |
| Residual DS < 50% | 107 (97.3) | 25 (100) | 49 (96.1) | 10 (90.9) | 23 (100) | 0.41 |
Values are n (%).
DS, diameter stenosis; ISR, in-stent restenosis; IVL, intravascular lithotripsy; TIMI, Thrombolysis in Myocardial Infarction; DES, drug-eluting stent; DCB, drug-coated balloon.